Novo Agrees to $32 Million Pact Ending Ozempic-Related Deal Case

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of technology used in the oral version of the blockbuster diabetes drug Ozempic.

The settlement disclosed Monday would resolve claims that Lionsgate chairman Mark Rachesky exploited his control of Emisphere Technologies Inc. to force the sale through on terms that steered value to insiders. The agreement requires court approval.

The Danish drug giant that became Europe’s most valuable company on the success of Ozempic and the obesity medication Wegovy wasn’t named as a defendant.

The payment will be made by ...